Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond.
Andrew GaballaShada JadamMilind Y DesaiPublished in: Expert opinion on pharmacotherapy (2024)
Mavacamten is the first-in-class CMI approved by the FDA to target HCM pathophysiology specifically. Mavacamten should be incorporated into the standard therapy for oHCM in case of symptom persistence despite using maximally tolerated beta blockers and/or calcium channel blockers. Potential drug-drug interactions should be assessed before initiating this drug. More studies are needed on the use of CMIs in patients with kidney and/or liver failure and pregnant/breastfeeding patients.
Keyphrases
- hypertrophic cardiomyopathy
- liver failure
- end stage renal disease
- left ventricular
- ejection fraction
- hepatitis b virus
- chronic kidney disease
- newly diagnosed
- angiotensin converting enzyme
- pregnant women
- preterm infants
- peritoneal dialysis
- patient reported
- emergency department
- adverse drug
- risk assessment
- human health
- climate change
- electronic health record